VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 357 EUR | +0.28% |
|
+0.42% | -0.70% |
| May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play |  |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated | |
ETFs positioned on Virbac
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 0 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 0 M€ | +3.63% | - | |
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -2.25% | - | |
| 0.00% | 0 M€ | -2.58% | - | |
| 0.00% | 0 M€ | -3.22% | - |
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.4%), Europe (26.2%), Latin America (17.1%), Asia (16.4%), North America (13.2%), Pacific (9.3%), Africa and Middle East (2.4%).
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
357
EUR
Average target price
368
EUR
Spread / Average Target
+3.08%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.70% | 3.22B | |
| -14.35% | 77.13B | |
| +14.09% | 8.4B | |
| +27.62% | 3.79B | |
| +14.70% | 1.64B | |
| -10.12% | 1.5B | |
| -22.60% | 1.3B | |
| -4.20% | 1.25B | |
| -10.26% | 1.18B | |
| +5.06% | 1.1B |
- Stock Market
- Equities
- VIRP Stock
- Funds and ETFs Virbac